Patents by Inventor Robert J. Connor

Robert J. Connor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250127866
    Abstract: In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.
    Type: Application
    Filed: November 7, 2024
    Publication date: April 24, 2025
    Applicant: Halozyme, Inc.
    Inventors: David W. KANG, Robert J. CONNOR, Tara NEKOROSKI, Todd J. LEADENS, II, Baylor FRANTZ, Scott BEACHER, Kevin SWANSON, Mike TRAVANTY
  • Publication number: 20250127865
    Abstract: In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.
    Type: Application
    Filed: November 7, 2024
    Publication date: April 24, 2025
    Applicant: Halozyme, Inc.
    Inventors: David W. KANG, Robert J. CONNOR, Tara NEKOROSKI, Todd J. LEADENS, II, Baylor FRANTZ, Scott BEACHER, Kevin SWANSON, Mike TRAVANTY
  • Patent number: 12178860
    Abstract: In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.
    Type: Grant
    Filed: December 22, 2023
    Date of Patent: December 31, 2024
    Assignee: Halozyme, Inc.
    Inventors: David W. Kang, Robert J. Connor, Tara Nekoroski, Todd J. Leadens, II, Baylor Frantz, Scott Beacher, Kevin Swanson, Mike Travanty
  • Publication number: 20240261376
    Abstract: In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.
    Type: Application
    Filed: April 22, 2024
    Publication date: August 8, 2024
    Applicant: Halozyme, Inc.
    Inventors: David W. KANG, Robert J. CONNOR, Tara NEKOROSKI, Todd J. LEADENS, II, Baylor FRANTZ, Scott BEACHER, Kevin SWANSON, Mike TRAVANTY
  • Publication number: 20240207375
    Abstract: In one aspect, the present disclosure provides a formulation comprising a hyaluronidase enzyme and a therapeutically effective amount of an active ingredient. In another aspect, the present disclosure provides a method of administering a high volume of the formulation in a single administration to treat a disease or disorder in a subject.
    Type: Application
    Filed: December 22, 2023
    Publication date: June 27, 2024
    Applicant: Halozyme Inc.
    Inventors: David W. KANG, Robert J. Connor, Tara Nekoroski, Todd J. Leadens, II, Baylor Frantz, Scott Beacher, Kevin Swanson, Mike Travanty
  • Patent number: 4312004
    Abstract: Electric signals are recorded on a recording medium having a light sensitivity extending to wavelengths shorter than 475 nm, with an array of electrically switched lanthanum modified lead zirconate titanate (PLZT) light gates located between a light polarizer and a complementary light analyzer. The light gates are illuminated through the polarizer with light whose wavelength essentially is longer than 475 nm. Such light is selectively gated through electrically switched light gates through the analyzer and to the recording medium having a light sensitivity extending to wavelengths shorter than 475 nm. Information recordings may be made in this manner over extended periods of time without the typical performance degradation through photoinduced birefringence observed with conventionalPLZT electrooptic shutters.
    Type: Grant
    Filed: May 7, 1979
    Date of Patent: January 19, 1982
    Assignee: Bell & Howell Company
    Inventors: Norbert E. Samek, Thomas H. Garland, Robert J. Connor